Drug Delivery Systems Market | 2021 Impact of COVID-19, Case Study Analysis, Key Opportunities and Major Players, Size, Growth, Share, Regional Analysis With Global Industry Forecast To 2027, The global “Drug Delivery Systems” Market is projected to reach USD 45.20 billion by 2027, exhibiting a CAGR of 6.8% during the forecast period. Increasing prevalence of multiple chronic conditions (MCCs) worldwide is expected to be the leading factor driving the growth of this market, finds Fortune Business Insights™ in its report, titled “Drug Delivery Systems Market Size, Share Industry Analysis, By Type (Inhalation, Transdermal, Injectables and Others), By Device Type (Conventional and Advanced), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others) and Regional Forecast, 2020-2027”.
MCCs refer to the existence of more than one chronic condition in an individual. According to a study published by the World Economic Forum (WEF), 33% of adults around the world suffer from a combination of MCCs such as cardiovascular disease with diabetes and depression or even cancer. Precision Drug Delivery Systems can play a crucial role in managing these conditions as they are able to administer drugs at the exact location of the disease. As incidence of chronic conditions rises, the demand for these systems is likely to spike in the coming years.
Major Drug Delivery Systems Market Key players covered in the report include:
- Pfizer Inc.(U.S)
- West Pharmaceutical Services, Inc.(U.S)
- Medtronic (Ireland)
- Baxter International Inc. (S)
- BD (Becton, Dickinson and Company)(U.S)
- Ypsomed (Switzerland)
- Nemera (France)
- Gerresheimer AG (Germany)
- 3M (S)
Get Request a Sample Copy of the Drug Delivery Systems Report:
https://www.fortunebusinessinsights.com/enquiry/sample/drug-delivery-systems-market-103070
Drug Delivery Systems Market Analysis 2021:
Regional Analysis
North America to Hold Dominant Lead in the Market; Europe to Follow Closely
Among regions, North America is expected to dominate this market share during the forecast period owing to the active adoption of advanced drug delivery systems, especially for care of the elderly populace. Besides this, increased funding for medical RD activities is also feeding the growth of this market. In 2019, the market size in the region was at USD 10.65 billion.
In Europe, the top growth driver is the rising prevalence of chronic diseases, coupled with the presence of large pharmaceutical companies, especially in Ireland, UK, Germany, and France. The market in Asia-Pacific is expected to be fueled by the expanding patient pool in India and China and the spreading awareness of the advantages of Drug Delivery Systems in the region.
As per the report findings, the market value was at USD 26.08 billion in 2019. The report also offers the following information:
- Comprehensive analysis of the impact of COVID-19 outbreak on the market;
- Detailed assessment of the market trends, drivers, and restraints;
- In-depth examination of the regional dynamics and competitive environment shaping the market; and
- Careful study of all the possible market segments.
Market Opportunity
Coronavirus Pandemic to Create Multiple Opportunities in the Market
The drug delivery systems market growth is set to enter an animated period on account of the exponential spread of the COVID-19 infection. With the absence of a vaccine, healthcare professionals have been forced to rely on curative measures to alleviate the suffering of COVID-19 patients. In such dire circumstances, there is growing reliance on efficient drug delivery mechanisms to provide quick treatment for the disease. Moreover, the situation has generated several innovation opportunities for companies. For instance, in May 2020, UK-based Senzer Drug Delivery Systems announced that it was working on creating inhalable targeted antivirals for COVID-19. Similar efforts are being made at the University of Texas at Austin where an innovative inhaled formulation of niclosamide is being developed to treat COVID-19 symptoms. Thus, the outbreak of the coronavirus pandemic has renewed the interest in drug delivery research and innovation.
Click here to for a more detailed short-term and long-term impact analysis of COVID-19 on this market.
Please visit: https://www.fortunebusinessinsights.com/drug-delivery-systems-market-103070
Drug Delivery Systems Highlights of the Report:
- Market Penetration: Comprehensive information on the product portfolios of the top players in the Supply Chain Analytics market.
- Product Development/Innovation: Detailed insights on the upcoming technologies, RandD activities, and product launches in the market
- Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market
- Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Supply Chain Analytics market
Competitive Landscape
Growing Investments in Innovation by Companies to Foster Healthy Competition
Commanding presence of large pharmaceutical and medical devices companies is emerging as the chief feature of competition in this market. These companies are making strategic investments in elevating their innovation capacities to bring out novel Drug Delivery Systems for patients and physicians.
Industry Developments:
December 2019: US-based Insulet Corporation released its flagship Omnipod DASH™ Insulin Management System in the Netherlands and the UK. The novel insulin delivery device is designed to provide insulin delivery non-stop for three days, removing the need for daily injections for diabetics. It also features a touchscreen for patients to manage their condition on their own.
February 2019: Finland-domiciled Orion Corporation collaborated with Propeller Health to integrate Orion’s Easyhaler® product line with Propeller’s digital therapeutics platform. The inhaler range from Orion is designed for patients suffering from COPD and asthma. The connection between the two will be enabled by a custom-built sensor which will be synched with a mobile app.
